Mumbai: Medico Remedies Ltd., a leading pharmaceutical company specializing in high-quality medicines, announced the successful completion of trial production rounds at its newly established state-of-the-art ointment manufacturing plant in Palghar.
The facility, measuring 15,000 square feet, has been built adjacent to the existing plant that manufactures tablets and other medicines. With a monthly capacity of up to 3 million tubes, this new manufacturing facility marks a significant milestone in Medico Remedies’ commitment to expanding its production capabilities and meeting the growing demand for ointments.
The completion of the trial production rounds signifies the successful integration of cutting-edge technology, rigorous quality control measures, and meticulous planning in the construction of the plant. Medico Remedies has spared no effort in ensuring that the new ointment manufacturing facility adheres to the highest industry standards and complies with all regulatory requirements.
Haresh Mehta, Chairman and Whole Time Director of Medico Remedies, expressed his satisfaction with the milestone achievement and shared his perspective on the company’s future plans.
“We are glad to announce that we have completed trial production rounds at the newly established state-of-the-art ointment manufacturing plant at Palghar,” said Haresh Mehta. “We believe that this new facility will effectively cater to the rapidly growing ointment industry, which is expanding at a remarkable rate of 17% year on year. With its compliance with revised schedule M standards and plans to apply for WHO GMP certification, this facility is well-positioned to meet global regulatory requirements. It will have an impressive capacity to manufacture up to 3 million tubes monthly.”
Mehta further emphasized the company’s strategic vision for the new plant, stating, “We are currently in advanced discussions with multiple global players for manufacturing collaborations. In the future, we intend to apply for certifications from UK MHRA, US FDA, and PIC/S, enabling us to enter regulated markets such as the USA and Europe.”
